Skip to main content

Infectious Disease Dynamics

  • Who we are
    • People
    • Collaborators
  • Projects
    • Cholera Dynamics
      • Data
    • COVID-19
    • Cross-Sectional Incidence Testing
    • Emerging Diseases
    • Fluscape
    • HIV Dynamics
    • Healthcare Epidemiology
    • Impetus
    • Measles & Rubella
    • Phylogenetic Study Design
  • Publications
  • Updates
  • Search
Search

Search form

  • Who we are
    • People
    • Collaborators
  • Projects
    • Cholera Dynamics
      • Data
    • COVID-19
    • Cross-Sectional Incidence Testing
    • Emerging Diseases
    • Fluscape
    • HIV Dynamics
    • Healthcare Epidemiology
    • Impetus
    • Measles & Rubella
    • Phylogenetic Study Design
  • Publications
  • Updates
  • Search
  • Home
  • Projects
  • Cross-Sectional Incidence Testing

Cross-Sectional Incidence Testing

Cross-Sectional Incidence Testing

The capacity to accurately estimate incidence of HIV and HCV from cross sectional surveys is critical to the determining the current state of the epidemic and assessing the impact of population level interventions. These methodologies are used for country level incidence estimates, such as the Population-based HIV Impact Assessment (currently being performed in 15 countries receiving PEPFAR funding), large intervention trials, and at an individual level (for all newly diagnosed persons in the UK).

Using biomarkers associated with recent infection, we have developed and validated testing algorithms to generate point estimates of incidence and incidence differences between paired surveys.  Both serologic (properties of the antibody response) and nucleic acid (viral diversity) have been exploited for this purpose.

Publications

Immune responses in Ugandan women infected with subtypes A and D HIV using the BED capture immunoassay and an antibody avidity assay.
Longosz AF, Morrison CS, Chen PL, Arts E, Nankya I, Salata RA, Franco V, Quinn TC, Eshleman SH, Laeyendecker O.
J Acquir Immune Defic Syndr, 2014: 65(4): 390-396, 10.1097/QAI.0000000000000006
Incorrect identification of recent HIV infection in adults in the United States using a limiting-antigen avidity assay.
Longosz AF, Mehta SH, Kirk GD, Margolick JB, Brown J, Quinn TC, Eshleman SH, Laeyendecker O.
AIDS, 2014: 28(8): 1227-32, 10.1097/QAD.0000000000000221.
HIV diversity as a biomarker for HIV incidence estimation: including a high-resolution melting diversity assay in a multiassay algorithm.
Cousins MM, Konikoff J, Laeyendecker O, Celum C, Buchbinder SP, Seage GR 3rd, Kirk GD, Moore RD, Mehta SH, Margolick JB, Brown J, Mayer KH, Koblin BA, Wheeler D, Justman JE, Hodder SL, Quinn TC, Brookmeyer R, Eshleman SH.
J Clin Microbiol, 2014: 52(1): 115-21, 10.1128/JCM.02040-13
Impact of HIV subtype on performance of the limiting antigen-avidity enzyme immunoassay, the bio-rad avidity assay, and the BED capture immunoassay in Rakai, Uganda.
Longosz AF, Serwadda D, Nalugoda F, Kigozi G, Franco V, Gray RH, Quinn TC, Eshleman SH, Laeyendecker O.
AIDS Res Hum Retroviruses, 2014: 30(4): 339-44, 10.1089/AID.2013.0169
Antibody maturation and viral diversification in HIV-infected women.
James MM, Laeyendecker O, Sun J, Hoover DR, Mullis CE, Cousins MM, Coates T, Moore RD, Kelen GD, Fowler MG, Kumwenda JJ, Mofenson LM, Kumwenda NI, Taha TE, Eshleman SH.
PLoS One, 2013: 8(2): e57350, 10.1371/journal.pone.0057350
Effect of natural and ARV-induced viral suppression and viral breakthrough on anti-HIV antibody proportion and avidity in patients with HIV-1 subtype B infection.
Wendel SK, Mullis CE, Eshleman SH, Blankson JN, Moore RD, Keruly JC, Brookmeyer R, Quinn TC, Laeyendecker O.
PLoS One, 2013: 8(2): e55525, 10.1371/journal.pone.0055525
Estimation of HIV incidence using multiple biomarkers.
Brookmeyer R, Konikoff J, Laeyendecker O, Eshleman SH.
Am J Epidemiol, 2013: 77(3): 264-72, 10.1093/aje/kws436
HIV incidence determination in the United States: a multiassay approach.
Laeyendecker O, Brookmeyer R, Cousins MM, Mullis CE, Konikoff J, Donnell D, Celum C, Buchbinder SP, Seage GR 3rd, Kirk GD, Mehta SH, Astemborski J, Jacobson LP, Margolick JB, Brown J, Quinn TC, Eshleman SH.
J Infect Dis, 2013: 207(2): 232-9, 10.1093/infdis/jis659

Pages

  • ‹ previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • next ›

Contact

Tel: 410-955-3551

Email: iddynam [at] jhu.edu

Infectious Disease Dynamics Group
c/o Justin Lessler
Johns Hopkins Bloomberg School of Public Health
615 North Wolfe Street, E6545
Baltimore MD 21205

Social

Twitter
 
  • Disclaimer & Privacy
  • Sitemap
© 2021 Infectious Disease Dynamics
Website by Manta Ray Media